A Phase I/II Study of the Safety, Tolerance, and Pharmacokinetics of 9-(2-Phosphonylmethoxyethyl)Adenine ( PMEA; Adefovir ) in Patients With Advanced HIV Disease.

NCT ID: NCT00002115


Title
A Phase I/II Study of the Safety, Tolerance, and Pharmacokinetics of 9-(2-Phosphonylmethoxyethyl)Adenine ( PMEA; Adefovir ) in Patients With Advanced HIV Disease.
Purpose
To study the safety, tolerance, pharmacokinetics, and anti-HIV effects of PMEA ( adefovir ) when administered daily by intravenous (IV) and/or subcutaneous (SC) injection in patients with advanced HIV disease.
Details
Patients receive a single IV or SC dose of PMEA daily for 4 weeks. A maximum tolerated dose will be defined for these regimens.
Conditions
HIV Infections
Keywords
Acquired Immunodeficiency Syndrome, Antiviral Agents, Adenine
Source
NIH AIDS Clinical Trials Information Service
Sponsors
Gilead Sciences
Status
Completed
Acronym
Last Updated
22 Jun 2005
URL
Official Link
Locations
United States